5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upChronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticariaActive, not recruitingPhase 32026-10-02NCT05677451
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)Infections, RNA Virus Infections, influenza, respiratory system disorder, respiratory tract infectious disorder, viral infectious diseaseActive, not recruitingPhase 32026-09-17NCT07159763
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorderActive, not recruitingPhase 32026-09-04NCT05739383
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsInfections, RNA Virus Infections, avian influenza, bird disease, influenza, non-human animal disease, respiratory system disorder, respiratory tract infectious disorder, viral infectious diseaseActive, not recruitingPhase 32026-08-11NCT07496450
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)HER2-Positive Primary Breast Cancer; Residual Invasive Breast CancerActive, not recruitingPhase 32026-05-15NCT04622319